DDInter1557 DDInter927
An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Quinine {u} (Compound) resembles {v} (Compound) Quinidine barbiturate
Quinine {u} (Compound) treats {v} (Disease) malaria
Quinine {u} (Compound) binds {v} (Gene) SLC22A4
Quinine {u} (Compound) upregulates {v} (Gene) CPVL
Quinine {u} (Compound) downregulates {v} (Gene) DNAJA3
Quinine {u} (Compound) causes {v} (Side Effect) Optic neuritis
Quinine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Quinine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doxycycline
Quinine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostemsavir
Quinine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aminoglutethimide
Quinine (Compound) resembles Quinidine barbiturate (Compound)
Quinine (Compound) treats malaria (Disease)
Quinine (Compound) binds SLC22A4 (Gene)
Quinine (Compound) upregulates CPVL (Gene)
Quinine (Compound) downregulates DNAJA3 (Gene)
Quinine (Compound) causes Optic neuritis (Side Effect)
Quinine may cause a minor interaction that can limit clinical effects when taken with Modafinil
Quinine may cause a minor interaction that can limit clinical effects when taken with Doxycycline
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide